Can Plaquenil (hydroxychloroquine) cause hypoglycemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

Hydroxychloroquine sulfate can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7)]. Measure blood glucose in patients presenting with clinical symptoms suggestive of hypoglycemia and as adjust the antidiabetic treatment as necessary Warn hydroxychloroquine sulfate-treated patients about the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia; diabetic patients should monitor their blood sugar levels. Advise patients to seek medical attention if they develop any signs and symptoms of hypoglycemia.

Yes, Plaquenil (hydroxychloroquine) can cause hypoglycemia. Patients should be warned about the risk of hypoglycemia and educated on its signs and symptoms. Diabetic patients should monitor their blood sugar levels, and all patients should seek medical attention if they develop any signs and symptoms of hypoglycemia 1, 1, 1.

From the Research

Yes, Plaquenil (hydroxychloroquine) can cause hypoglycemia as a side effect, particularly in patients with diabetes, as evidenced by a recent case report in 2024 2. This medication, commonly used to treat autoimmune conditions like rheumatoid arthritis and lupus, has been shown to lower blood glucose levels. The hypoglycemic effect occurs because hydroxychloroquine increases insulin sensitivity in peripheral tissues and may enhance pancreatic insulin secretion. Some key points to consider:

  • Patients taking insulin or other diabetes medications alongside Plaquenil may be at higher risk for hypoglycemic episodes and might require adjustment of their diabetes medications.
  • The hypoglycemic effect can occur at standard therapeutic doses (typically 200-400 mg daily for adults) and may develop even after long-term use, as seen in a study from 2021 3.
  • Patients should monitor their blood glucose levels regularly, especially when starting Plaquenil or changing dosages, and should be aware of hypoglycemia symptoms such as shakiness, sweating, confusion, and heart palpitations.
  • If experiencing these symptoms, patients should check their blood sugar and treat low levels promptly with fast-acting carbohydrates. It's also worth noting that hydroxychloroquine has been associated with hypoglycemia in patients without diabetes, as reported in a case study from 2024 2, highlighting the need for careful monitoring of blood glucose levels in all patients taking this medication.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.